AR072441A1 - Procedimiento para la obtencion de un concentrado de factor von willebrand o del complejo de factor viii/factor von willebrand y utilizacion de los mismos - Google Patents
Procedimiento para la obtencion de un concentrado de factor von willebrand o del complejo de factor viii/factor von willebrand y utilizacion de los mismosInfo
- Publication number
- AR072441A1 AR072441A1 ARP090100004A ARP090100004A AR072441A1 AR 072441 A1 AR072441 A1 AR 072441A1 AR P090100004 A ARP090100004 A AR P090100004A AR P090100004 A ARP090100004 A AR P090100004A AR 072441 A1 AR072441 A1 AR 072441A1
- Authority
- AR
- Argentina
- Prior art keywords
- von willebrand
- factor
- willebrand factor
- concentrate
- procedure
- Prior art date
Links
- 108010047303 von Willebrand Factor Proteins 0.000 title abstract 6
- 102100036537 von Willebrand factor Human genes 0.000 title abstract 6
- 229960001134 von willebrand factor Drugs 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 4
- 239000012141 concentrate Substances 0.000 title abstract 3
- 238000001728 nano-filtration Methods 0.000 abstract 3
- 229940003169 factor viii / von willebrand factor Drugs 0.000 abstract 2
- 102100026735 Coagulation factor VIII Human genes 0.000 abstract 1
- 108010054218 Factor VIII Proteins 0.000 abstract 1
- 102000001690 Factor VIII Human genes 0.000 abstract 1
- 201000003542 Factor VIII deficiency Diseases 0.000 abstract 1
- 208000009292 Hemophilia A Diseases 0.000 abstract 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 abstract 1
- 208000027276 Von Willebrand disease Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229960000301 factor viii Drugs 0.000 abstract 1
- 239000011148 porous material Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 208000012137 von Willebrand disease (hereditary or acquired) Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
- A61L2/0017—Filtration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
Abstract
Reivindicacion 1: Procedimiento para la obtencion de un concentrado de factor von Willebrand o del complejo Factor VIII/Factor von Willebrand, de origen humano o recombinante, caracterizado por: a) preparacion de una solucion de factor von Willebrand o de complejo de Factor VIII/Factor von Willebrand que contiene FVW a una concentracion de hasta 12 UI FVWRCo/ml y una proporcion entre Factor von Willebrand/Factor VIII superior o igual a 0,4; b) proceder a la nanofiltracion de la solucion preparada en (a) mediante un filtro de tamano de poro menor de 35 nanometros. Reivindicacion 6: Procedimiento de nanofiltracion, segun las reivindicaciones anteriores, caracterizado por que el Factor von Willebrand recuperado después de la nanofiltracion mantiene una estructura multimérica que incluye multímeros del orden de 11 o superior. Reivindicacion 15: Utilizacion del concentrado obtenido segun el procedimiento de las reivindicaciones anteriores para la preparacion de un medicamento para su uso en el tratamiento de la Hemofilia A o de la enfermedad de von Willebrand.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200800021A ES2298096B1 (es) | 2008-01-08 | 2008-01-08 | Procedimiento para la obtencion de un concentrado de factor von willebrand o del complejo de factor viii/factor von willebrand y utilizacionde los mismos. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR072441A1 true AR072441A1 (es) | 2010-09-01 |
Family
ID=39316136
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090100004A AR072441A1 (es) | 2008-01-08 | 2009-01-05 | Procedimiento para la obtencion de un concentrado de factor von willebrand o del complejo de factor viii/factor von willebrand y utilizacion de los mismos |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US8354505B2 (es) |
| EP (1) | EP2078730B9 (es) |
| JP (1) | JP4976366B2 (es) |
| CN (1) | CN101480490B (es) |
| AR (1) | AR072441A1 (es) |
| AT (1) | ATE509031T1 (es) |
| AU (1) | AU2008255137C1 (es) |
| BR (1) | BRPI0900057B8 (es) |
| CA (1) | CA2645701C (es) |
| CL (1) | CL2009000022A1 (es) |
| ES (2) | ES2298096B1 (es) |
| HK (1) | HK1129075A1 (es) |
| MX (1) | MX2008015892A (es) |
| NZ (1) | NZ573400A (es) |
| PL (1) | PL2078730T3 (es) |
| PT (1) | PT2078730E (es) |
| RU (1) | RU2417096C2 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2861395B1 (fr) * | 2003-10-23 | 2006-02-17 | Lab Francais Du Fractionnement | Facteur viii viralement securise a faible teneur en multimeres superieurs |
| US11197916B2 (en) | 2007-12-28 | 2021-12-14 | Takeda Pharmaceutical Company Limited | Lyophilized recombinant VWF formulations |
| JP5784907B2 (ja) * | 2007-12-28 | 2015-09-24 | バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ | 組換え型ｖｗｆ製剤 |
| TWI593421B (zh) | 2008-10-21 | 2017-08-01 | 巴克斯歐塔公司 | 凍乾的重組ｖｗｆ調配物 |
| KR101969515B1 (ko) * | 2011-06-10 | 2019-04-16 | 박스알타 인코퍼레이티드 | 재조합 vwf의 투여에 의한 응고 질환의 치료 |
| WO2012176876A1 (ja) * | 2011-06-24 | 2012-12-27 | 旭化成メディカル株式会社 | 蛋白製剤の製造方法 |
| US11370827B2 (en) * | 2012-01-12 | 2022-06-28 | Bioverativ Therapeutics Inc. | Chimeric factor VIII polypeptides and uses thereof |
| US20150080309A1 (en) | 2012-04-24 | 2015-03-19 | Nova Nordisk A/S | Compounds Suitable for Treatment of Haemophilia |
| CN105705516B (zh) * | 2013-11-08 | 2019-11-01 | 杰特有限公司 | 浓缩von Willebrand因子或其络合物的方法 |
| DK3152230T3 (da) * | 2014-06-06 | 2019-11-11 | Octapharma Ag | Præparat omfattende faktor viii og von willebrand-faktor-peptider |
| CN104804078B (zh) * | 2015-05-05 | 2019-01-04 | 广东卫伦生物制药有限公司 | 人体血清凝血因子ⅷ中的病毒过滤方法 |
| JP2020531516A (ja) * | 2017-08-23 | 2020-11-05 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | フォン・ウィルブランド因子のウイルスろ過の方法 |
| AU2022326188A1 (en) | 2021-08-11 | 2024-02-22 | Grifols Worldwide Operations Limited | Method for producing human plasma-derived factor viii / von willebrand factor and composition obtained |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5110907A (en) * | 1989-08-01 | 1992-05-05 | Alpha Therapeutic Corporation | Factor viii complex purification using heparin affinity chromatography |
| US5288853A (en) * | 1992-04-30 | 1994-02-22 | Alpha Therapeutic Corporation | Factor viii purification process |
| EP0860444A1 (en) * | 1997-02-24 | 1998-08-26 | Stichting Centraal Laboratorium van de Bloedtransfusiedienst van het Nederlandse Rode Kruis (CLB) | Method for removing viruses from a protein solution |
| AT406373B (de) | 1997-02-27 | 2000-04-25 | Immuno Ag | Verfahren zur reinigung von faktor viii/vwf-komplex mittels kationenaustauscherchromatographie |
| AT405485B (de) * | 1997-05-28 | 1999-08-25 | Immuno Ag | Eine das vwf-propeptid enthaltende pharmazeutische präparation |
| FR2772381B1 (fr) * | 1997-12-15 | 2001-06-08 | Lab Francais Du Fractionnement | Procede de preparation par filtration d'une solution de facteur viii securisee viralement |
| FR2861395B1 (fr) * | 2003-10-23 | 2006-02-17 | Lab Francais Du Fractionnement | Facteur viii viralement securise a faible teneur en multimeres superieurs |
| FR2874216B1 (fr) * | 2004-08-16 | 2006-11-03 | Lab Francais Du Fractionnement | Procede de preparation d'un concentre de facteur von willebrand (fvw) par voie chromatographique et concentre de fvw susceptible d'etre ainsi obtenu |
-
2008
- 2008-01-08 ES ES200800021A patent/ES2298096B1/es active Active
- 2008-11-28 EP EP08380326A patent/EP2078730B9/en not_active Revoked
- 2008-11-28 PT PT08380326T patent/PT2078730E/pt unknown
- 2008-11-28 AT AT08380326T patent/ATE509031T1/de active
- 2008-11-28 PL PL08380326T patent/PL2078730T3/pl unknown
- 2008-11-28 ES ES08380326T patent/ES2363827T3/es active Active
- 2008-12-03 CA CA2645701A patent/CA2645701C/en active Active
- 2008-12-03 NZ NZ573400A patent/NZ573400A/en not_active IP Right Cessation
- 2008-12-04 AU AU2008255137A patent/AU2008255137C1/en active Active
- 2008-12-09 CN CN2008101840044A patent/CN101480490B/zh active Active
- 2008-12-11 MX MX2008015892A patent/MX2008015892A/es active IP Right Grant
- 2008-12-24 JP JP2008328536A patent/JP4976366B2/ja active Active
- 2008-12-26 RU RU2008151957/15A patent/RU2417096C2/ru not_active IP Right Cessation
-
2009
- 2009-01-05 AR ARP090100004A patent/AR072441A1/es active IP Right Grant
- 2009-01-06 BR BRPI0900057A patent/BRPI0900057B8/pt active IP Right Grant
- 2009-01-07 US US12/349,604 patent/US8354505B2/en active Active
- 2009-01-07 CL CL2009000022A patent/CL2009000022A1/es unknown
- 2009-10-05 HK HK09109192.8A patent/HK1129075A1/xx not_active IP Right Cessation
-
2011
- 2011-06-20 US US13/164,117 patent/US20110275570A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP4976366B2 (ja) | 2012-07-18 |
| HK1129075A1 (en) | 2009-11-20 |
| US20110275570A1 (en) | 2011-11-10 |
| NZ573400A (en) | 2010-02-26 |
| EP2078730A1 (en) | 2009-07-15 |
| ES2298096A1 (es) | 2008-05-01 |
| BRPI0900057A2 (pt) | 2009-09-22 |
| ES2298096B1 (es) | 2009-01-01 |
| AU2008255137B2 (en) | 2011-04-07 |
| CL2009000022A1 (es) | 2009-11-20 |
| EP2078730B9 (en) | 2011-12-21 |
| AU2008255137C1 (en) | 2015-08-27 |
| RU2008151957A (ru) | 2010-07-10 |
| BRPI0900057B1 (pt) | 2021-03-23 |
| CA2645701A1 (en) | 2009-07-08 |
| RU2417096C2 (ru) | 2011-04-27 |
| PL2078730T3 (pl) | 2011-10-31 |
| JP2009161528A (ja) | 2009-07-23 |
| CA2645701C (en) | 2013-09-17 |
| EP2078730B1 (en) | 2011-05-11 |
| MX2008015892A (es) | 2009-07-07 |
| PT2078730E (pt) | 2011-07-14 |
| ATE509031T1 (de) | 2011-05-15 |
| CN101480490A (zh) | 2009-07-15 |
| CN101480490B (zh) | 2013-05-29 |
| AU2008255137A1 (en) | 2009-07-23 |
| ES2363827T3 (es) | 2011-08-17 |
| US20090176709A1 (en) | 2009-07-09 |
| US8354505B2 (en) | 2013-01-15 |
| BRPI0900057B8 (pt) | 2021-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR072441A1 (es) | Procedimiento para la obtencion de un concentrado de factor von willebrand o del complejo de factor viii/factor von willebrand y utilizacion de los mismos | |
| BR112015025464A2 (pt) | coagonistas do receptor de glp-1/glucagon estáveis, prolongados para uso médico | |
| CL2015003117A1 (es) | Modificaciones en la estructura cristalina | |
| PE20181338A1 (es) | Vectores del factor viii del virus adeno-asociado, particulas viricas asociadas y formulaciones terapeuticas que los comprenden | |
| GT200500254A (es) | Proceso para la concentracion de anticuerpos y productos terapeùticos relacionados. | |
| ES2721325T3 (es) | Método para producir de manera estéril partículas de lípido-ácido nucleico | |
| EA201491934A1 (ru) | Аналоги глюкагоноподобного пептида-2 (glp-2) | |
| AR086904A1 (es) | Tratamiento de trastornos de la coagulacion por medio de la administracion de factor recombinante de von willebrand (vwf) | |
| AR091967A1 (es) | Articulo de fabricacion que comprende aflibercept o 2iv-aflibercept | |
| MY181626A (en) | Treatment of diabetes mellitus by long-acting formulations of insulins | |
| PE20141012A1 (es) | Dimaleato de 9-[4-(3-cloro-2-fluoro-fenilamino)-7-metoxi-quinazolin-6-iloxi]-1,4-diaza-espiro[5.5]undecan-5-ona, su uso como medicamento y su preparacion | |
| CY1115961T1 (el) | Ανυδρη μορφη κρυσταλλικης μηλεϊνικης ορβεπιταντης (orvepitant maleate) | |
| BR112014012460A2 (pt) | proteínas recombinantes e seus usos terapêuticos | |
| CO7101247A2 (es) | Formulaciones de ácido poliinosínico-policitidílico (poli(i:c)) para el tratamiento de infecciones de las vías respiratorias altas | |
| MX2017013564A (es) | Formulaciones de glucopiranosil lipido a y alérgenos de cacahuete para administración sublingual. | |
| PE20171246A1 (es) | Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para la preparacion y uso de los mismos | |
| AR094291A1 (es) | Formulacion inyectable de liberacion prolongada que comprende tolvaptan opticamente activo, y un procedimiento para producirla | |
| PE20090653A1 (es) | Formulacion inmunogenica, porque comprende una cepa recombinante atenuada de mycobacterium, preferentemente la cepa recombinante bacilo de calmette y guerin (bcg), que expresa al menos una proteina o fragmento inmunogenico del virus respiratorio sinc | |
| PE20160842A1 (es) | Piperidiniltetrahidroquinolinas sustituidas | |
| PE20190966A1 (es) | Factor viii direccionado a los globulos rojos y metodo para su uso | |
| PE20070711A1 (es) | Derivados de piperazina utiles como antagonistas de ccr5 | |
| AR091977A1 (es) | El uso de antitrombina en la oxigenacion de membranas extracorporeas | |
| CO7170181A2 (es) | Nueva composición de alfentanilo para el tratamiento del dolor agudo | |
| ATE422905T1 (de) | Verbandsmaterial mit wirkstoffen | |
| AR074724A1 (es) | Sal de citrato 11-(2-pirrolidin-1-il-etoxi)-14,19-dioxa-5,7,26-triaza-tetraciclo (19.3.1.1(2,6).1(8,12) heptacosa-1-(25),2(26),3,5,8,10,12 (27),16,21,23-decaeno |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |